Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-2752 Monotherapy and Combination in Solid Tumors and Lymphoma
NCT03739931Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2018
- Primary completion
- Aug 2025
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 1, open-label trial of mRNA-2752 in solid tumor, lymphoma, triple-negative breast cancer (TNBC) and 5 more (3 arms), sponsored by Moderna Inc. Primary endpoints: Dose Limiting Toxicities, Adverse Events up to 27 months and 1 more. Started Nov 2018; status: completed.
02
Drugs
mRNA-2752
03
Conditions
solid tumorlymphomatriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03739931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739931.